AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Arcadia Biosciences Reports Q2 Loss of $4.5 Million, Revenue of $1.5 Million.
ByAinvest
Friday, Aug 15, 2025 5:12 am ET1min read
Arcadia Biosciences reported a Q2 loss of $4.5 million, or $3.26 per share, and revenue of $1.5 million. The agricultural biotechnology trait company's adjusted earnings per share were 2 cents.
Arcadia Biosciences, Inc. (Nasdaq: RKDA), a producer and marketer of innovative wellness products, reported its financial results for the second quarter and first half of 2025. The company experienced an 11% increase in total revenues year over year, driven by a significant 24% growth in Zola® coconut water sales. Despite this revenue growth, Arcadia reported a net loss of $4.5 million for the second quarter, an increase from the net income of $1.1 million in Q2 2024 [1].Arcadia's adjusted earnings per share (EPS) were 2 cents for the quarter, down from 16 cents in Q2 2024. The company's gross margins have consistently exceeded 30% for ten consecutive quarters, indicating strong operational efficiency. However, total operating expenses rose dramatically by 390% in Q2 2025, suggesting escalating costs could impact future profitability [1].
Arcadia also announced the receipt of 2.7 million shares of stock in Above Food Ingredients Inc. as partial repayment related to a previous sale. This, along with the elimination of $1 million in contingent liabilities, brings the total eliminated to $2 million year-to-date [1]. The company continues to pursue the repayment of the remaining outstanding balance of the note receivable related to the sale of GoodWheat™ assets.
Arcadia's pending business combination with Roosevelt Resources continues to move forward. The company recently filed an amendment to the initial Form S-4 registration statement to provide responses to comments received from the SEC and to provide updated financial information through the first quarter of 2025 for both Arcadia Biosciences and Roosevelt Resources [1].
References:
[1] https://www.quiverquant.com/news/Arcadia+Biosciences+Reports+11%25+Revenue+Growth+Driven+by+24%25+Increase+in+Zola%C2%AE+Sales+and+Reduces+Liabilities+by+%241+Million
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet